Современные методы оценки активности системной красной волчанки

1. <div><p>Isenberg D. BILAG, SLEDAI, SIS, ECLAM, WAM, SLAM.. Thank you MAM. Lupus 2007;16:849-51.</p><p>Liang M.H., Socher S.A., Roberts W.N. et al. Measurement of systemic lupus erythematosus activity in clinical research. Arthr Rheum 1988;31:817-25.</p><p>Yee Chee-Seng. Development and validation of the BILAG-2004 Index for the assessment of disease activity in SLE. Rheumatology Research Group Division of Infection and Immunology, School of Medicine, The University of Birmingham. A thesis submitted to The University of Birmingham for the degree of doctor of philosophy. 2008; February.</p><p>Bombardier C., Gladman D.D., Urowitz M.B. et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthr Rheum 1992;35:630—40.</p><p>Liang M.H., Socher S.A., Larson M.G. et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthr Rheum 1989;32:1107-18.</p><p>Vitali C., Bencivelli W., Isenberg D.A. et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:541-7.</p><p>Petri M., Hellmann D., Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53—9.</p><p>Hay E.M., Bacon P.A., Gordon C. et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.</p><p>Guidance for Industry, Systemic Lupus Erythematosus — Developing Medical Products for Treatment. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Center for Biologics Evaluation and Research (CBER). Center for Devices and Radiological Health (CDRH). 2010; June.</p><p>Mosca M., Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006;24:100-4.</p><p>Freire Е.А.М., Souto L.M., Ciconelli R.M. Assessment measures in systemic lupus erythematosus. Rev Bras Reumatol 2011;51:70—80.</p><p>Guzman J., Cardiel M.H., Arce-Salinas A. et al. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.</p><p>Khanna S., Pal H., Pandey R.M., Handa R. The relationship between disease activity and quality of life in systemic lupus erythematosus. Rheumatology 2004;43:1536-40.</p><p>Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.</p><p>Petri M., Kim M.Y., Kalunian K.C. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550—8.</p><p>Petri М., Buyon J., Kalunian K. et al. Revision of the SELENA Flare Index. Arthr Rheum 2009;60, Abstract Suppl The 2009 ACR/ARHP Annual Scientific Meeting. Philadelphia, October 16—21, 2009.</p><p>Symmons D.P., Coppock J.S., Bacon P.A. et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988;69:927-37.</p><p>Hay E.M., Bacon P.A., Gordon C. et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.</p><p>Sivaraj R.R., Durrani O.M., Denniston A.K. et al. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford) 2007;46:1757-62.</p><p>Lee C.K., Ahn M.S., Lee E.Y. et al. Acute abdominal pain in systemic lupus erythematosus: focus on lupus enteritis (gastrointestinal vasculitis). Ann Rheum Dis 2002;61:547-50.</p><p>Hallegua D.S., Wallace D.J. Gastrointestinal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol 2000;12:379—85.</p><p>Isenberg D., Rahman A., Allen E. et al. BILAG-2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902—6.</p><p>Yee Chee-Seng, Farewell V., Isenberg D. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology 2009;48:691-5.</p><p>Stoll T., Stucki G., Malik J. et al. Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997;24:309-13.</p><p>Cresswell L., Yee Chee-Seng, Farewell V. Numerical scoring for the Classic BILAG index. Rheumatology 2009;48:1548-52.</p><p>Yee Chee-Seng, Cresswell L., Farewell V. Numerical scoring for the BILAG-2004 index. Rheumatology 2010;49:1665-9.</p><p>Isenberg D.A., Gordon C. From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000;9:651-4.</p><p>Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthr Rheum 2010;62:222-33.</p><p>Wallace D., Stohl W., Furie R. A phase II, randomized, doubleblind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthr Rheum 2009;61:1168—78.</p><p>Furie R., Petri M., Wallace D. Novel Evidence-Based Systemic Lupus Erythematosus Responder Index. Arthr Rheum 2009;61:1143—51.</p><p>Dall’era M., Chakravarty E.F. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep 2011;4:308-16.</p><p>Tullus K. New developments in the treatment of systemic lupus erythematosus. Pediatr Nephrol 2012;27:727-32.</p><p>Gunnarsson I., van Vollenhoven R.F. Biologicals for the treatment of systemic lupus erythematosus? Ann Med 2012;44:225-32.</p><p>Fanouriakis A., Boumpas D.T., Bertsias G.K. Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. Expert Rev Clin Pharmacol 2011;4:437-51.</p></div><br />